FDA Aligns Oncolytics on Randomized Pelareorep Trial Showing 82% 12-Month Survival
Oncolytics secured FDA alignment on a randomized controlled pivotal trial for pelareorep in unresectable metastatic SCAC, aiming for both accelerated and full approval. Prior second-line data showed pelareorep plus checkpoint inhibitor achieved median 15.5-month response duration versus 9.5 months and 82% 12-month survival versus 45.7%.
1. FDA Alignment on Pivotal Trial Design
Oncolytics engaged the FDA in a Type C meeting to align on a randomized controlled pivotal trial design for pelareorep in unresectable metastatic squamous cell carcinoma of the anal canal. The trial is structured to support accelerated approval based on early endpoints and full approval upon demonstration of durability and survival benefits.
2. Pivotal Study Focus and Patient Population
The study will enroll patients who have progressed after first-line chemotherapy and checkpoint inhibitors, a group lacking FDA-approved treatments. It will compare pelareorep plus standard care against standard care alone to meet rigorous evidentiary standards within a single protocol.
3. Efficacy Data Supporting Trial
In second-line SCAC, pelareorep combined with a checkpoint inhibitor achieved a median response duration of 15.5 months versus 9.5 months and 12-month survival of 82% compared to 45.7% on current standard therapies. These data signal a substantial improvement in survival and durability for this high-need patient population.
4. Development and Commercial Outlook
Oncolytics plans to finalize the protocol incorporating FDA feedback and anticipates initiating the randomized trial later this year. With Fast Track designations in gastrointestinal cancers and active partnership discussions, the company aims to accelerate development and maximize pelareorep’s commercial impact.